AV-101, VistaGen’s Oral NMDA Receptor Modulator, Granted FDA Fast-Track Designation for Major Depressive Disorder Key AV-101 Patents Issued in U.S., Europe and Asia ELEVATE, AV-101 U.S. Phase 2 Major Depressive Disorder Study, Patient Dosing Initiated and Study Continues SOUTH SAN FRANCISCO,

SOUTH SAN FRANCISCO, Calif., June 13, 2018 (GLOBE NEWSWIRE) --  VistaGen Therapeutics, Inc.  (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders, today announced that the U.S.

Patent Covers Methods for Producing Blood Cells, Platelets and Bone Marrow Stem Cells SOUTH SAN FRANCISCO, Calif., June 11, 2018 (GLOBE NEWSWIRE) --  VistaGen Therapeutics, Inc.  (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other

SOUTH SAN FRANCISCO, Calif., May 23, 2018 (GLOBE NEWSWIRE) --  VistaGen Therapeutics, Inc.  (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) disorders, and its wholly-owned stem cell

SOUTH SAN FRANCISCO, Calif., May 02, 2018 (GLOBE NEWSWIRE) --  VistaGen Therapeutics, Inc.  (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) disorders, today announced that the Japanese Patent Office

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/10/18 --  VistaGen Therapeutics, Inc.  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) disorders, today announced the European Patent Office has issued

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/05/18 --  VistaGen Therapeutics, Inc.  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) disorders, today announced the initiation of ELEVATE, the

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 03/19/18 --  VistaGen Therapeutics Inc.  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) disorders, today announced receiving a Notice of Allowance from

SAN FRANCISCO, CA -- (Marketwired) -- 03/07/18 --  VistaGen Therapeutics Inc.  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) disorders, today announced receiving a Notice of Allowance from the

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 03/05/18 --  VistaGen Therapeutics Inc.  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that  Shawn Singh, Chief Executive